Drug firm Neuland Laboratories Ltd on Friday (November 7) reported a net profit of ₹129 crore for the second quarter of FY26, up 166% from ₹48.5 crore in the same period last year.
Revenue for the quarter grew 63.7% year-on-year to ₹516 crore from ₹315.2 crore in Q2 FY25. Earnings before interest, tax, depreciation, and amortisation (EBITDA) increased to ₹156.9 crore from ₹65.7 crore a year ago. The company’s EBITDA margin improved to 30.4% from 20.8% in the corresponding quarter last year.
Sucheth Davuluri, Vice-Chairman and Chief Executive Officer, said, “The record high revenue this quarter, driven by CMS commercial projects, led to the operating leverage reflected in the EBITDA margins, and we expect this momentum to continue through the rest of the year.Also Read: Neuland Laboratories shares tank 11% despite FY26 growth assurance, Goldman optimism
Given the investments we are making, Neuland is well-positioned to take advantage of the number of growth opportunities available to us in both the CDMO as well as the generic APIs space.”
Saharsh Davuluri, Vice Chairman and Managing Director, Neuland Laboratories, said, “Customer interest in Neuland’s capabilities continues to be on the rise as we see increased engagement with a diverse range of customers.Our reputation and track record as an agile partner is enabling not just new business but for greater share of business from existing customers. Our investments are going according to plan and helping to further differentiate Neuland as a partner of choice.”
Also Read: Neuland Laboratories gets SEBI’s administrative warning for insider trading violation
Shares of Neuland Laboratories Ltd ended at ₹17,760.00, up by ₹207.15, or 1.18%, on the BSE.
First Published: Nov 7, 2025 7:17 PM IS
